I have just found article "Preclinical safety evaluation of inhaled cyclosporine in propylene glycol." (i have not enough post to give a link here

)
I am not able to get the full text, but the second sentence from the end of abstract is interesting for us:
The important thing is that in this case they made rats to inhale PG like we do
Here is the linked source of this document:
Preclinical Safety Evaluation of Inhaled Cyclosporine in Propylene Glycol
Here is the full text article which puts it into context:
Titre du document / Document title
Preclinical Safety Evaluation of Inhaled Cyclosporine in Propylene Glycol
Auteur(s) / Author(s)
TAO WANG (1) ; NOONBERG Sarah (1) ; STEIGERWALT Ronald (1) ; LYNCH Maryellen (2) ; KOVELESKY Rosemary A. (1) ; RODRIGUEZ Carlos A. (1) ; SPRUGEL Katherine (1) ; TURNER Nancy (1) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Novartis Pharmaceuticals, Safety Profiling and Assessment, Emeryville, California, ETATS-UNIS
(2) Battelle, Toxicology Battelle Columbus, Columbus, Ohio, ETATS-UNIS
Résumé / Abstract
Cyclosporine inhalation solution has the potential to improve outcomes following lung transplantation by delivering high concentrations of an immunosuppressant directly to the allograft while minimizing systemic drug exposure and associated toxicity. The objective of these studies was to evaluate the potential toxicity of aerosolized cyclosporine formulated in propylene glycol when given by inhalation route to rats and dogs for 28 days. Sprague-Dawley rats received total inhaled doses of 0 (air), 0 (vehicle, propylene glycol), 7.4, 24.3, and 53.9 mg cyclosporine/kg/day. In a separate study, beagle dogs were exposed to 0, 4.4, 7.7, and 9.7 mg cyclosporine/kg/day. Endpoints used to evaluate potential toxicity of inhaled cyclosporine were clinical observations, body weight, food consumption, respiratory functions, toxicokinetics, and clinical/anatomic pathology. Daily administration of aerosolized cyclosporine did not result in observable accumulation of cyclosporine in blood or lung tissue. Toxicokinetic analysis from the rat study showed that the exposure of cyclosporine was approximately 18 times higher in the lung tissue compared to the blood. Systemic effects were consistent with those known for cyclosporine. There was no unexpected systemic toxicity or clinically limiting local respiratory toxicity associated with inhalation exposure to cyclosporine inhalation solution at exposures up to 2.7 times the maximum human exposure in either rats or dogs. There were no respiratory or systemic effects of high doses of propylene glycol relative to air controls. These preclinical studies demonstrate the safety of aerosolized cyclosporine in propylene glycol and support its continued clinical investigation in patients undergoing allogeneic lung transplantation.
Revue / Journal Title
Journal of aerosol medicine
ISSN 0894-2684
CODEN JAEMEP
Source / Source
2007, vol. 20, no4, pp. 417-428 [12 page(s) (article)] (25 ref.)
Langue / Language
Anglais
Editeur / Publisher
Liebert, Larchmont, NY, ETATS-UNIS (1988-2007) (Revue)
Mots-clés anglais / English Keywords
Pharmaceutical technology ; Aerosols ; Propanediol ; Immunosuppressive agent ; Ciclosporin ; Inhalation ; Evaluation ; Safety ; Toxicity ; Preclinical trial ;
Mots-clés français / French Keywords
Inhibiteur de la calcineurine ; Technologie pharmaceutique ; Aérosol ; Propanediol ; Immunodépresseur ; Ciclosporine ; Inhalation ; Evaluation ; Sécurité ; Toxicité ; Essai préclinique ;
Mots-clés espagnols / Spanish Keywords
Tecnología farmacéutica ; Aerosol ; Propanodiol ; Inmunodepresor ; Ciclosporina ; Inhalación ; Evaluación ; Seguridad ; Toxicidad ; Ensayo preclínico ;
Mots-clés d'auteur / Author Keywords
aerosolized cyclosporine ; preclinical evaluation ; propylene glycol ; toxicity ;
Localisation / Location
INIST-CNRS, Cote INIST : 21577, 35400016270820.0030